Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Pulmonary Embolism I: Introduction

Pulmonary Embolism I: Introduction

Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A Multicenter, Double-Blind, Placebo-Controlled, Randomized Clinical Trial of Oral Anticoagulation in Systemic Sclerosis-Related Pulmonary Arterial Hypertension-Results From the SPHInX Study.

Pulmonary circulation·2026

Same author

Idiopathic Pulmonary Fibrosis update, comparing the Australasian Interstitial Lung Disease Registry to the Australian Idiopathic Pulmonary Fibrosis Registry.

Internal medicine journal·2026

Same author

Immunotherapy rechallenge after significant toxicity - can it be done successfully?

Immunotherapy·2025

Same author

Home spirometry appears accurate and feasible for monitoring chronic respiratory disease.

ERJ open research·2024

Same author

The impact of the 2022 Ukraine/Russian conflict on cancer clinical trials.

The Journal of international medical research·2022

Same author

Paroxysmal atrial fibrillation.

BMJ (Clinical research ed.)·2021

Search research articles

Related Experiment Video

Updated: May 21, 2026

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease

Published on: August 24, 2019

Exercise intolerance in pulmonary arterial hypertension.

Robin M Fowler¹, Kevin R Gain, Eli Gabbay

¹Advanced Lung Disease Program, Royal Perth Hospital, Level 3 Ainslie House, Murray Street, Western Australia 6000, GPO Box 2213, Perth, WA 6847, Australia.

Pulmonary Medicine

|June 28, 2012

Summary

Pulmonary arterial hypertension (PAH) causes exercise limitation due to dyspnea and fatigue. This review examines the right ventricle's role in these symptoms and exercise intolerance in PAH patients.

More Related Videos

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

Related Experiment Videos

Last Updated: May 21, 2026

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease

Published on: August 24, 2019

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

Area of Science:

Cardiology
Pulmonology
Exercise Physiology

Background:

Pulmonary arterial hypertension (PAH) presents with dyspnea and fatigue, limiting exercise capacity.
The precise mechanisms and clinical significance of these symptoms in PAH remain unclear.
Healthcare providers face uncertainty regarding acceptable symptom levels during exertion for PAH patients.

Purpose of the Study:

To explore the contribution of right ventricle (RV) dysfunction to exercise limitation and symptoms in PAH.
To investigate systemic and peripheral abnormalities contributing to exercise intolerance.
To examine the relationship between exercise abnormalities, symptoms, and RV function, and the utility of cardiopulmonary exercise testing (CPET).

Main Methods:

Literature review and synthesis of existing research on PAH, RV function, and exercise physiology.
Analysis of studies investigating the causes of dyspnea and fatigue in PAH.
Exploration of the role of cardiopulmonary exercise testing in assessing RV dysfunction.

Main Results:

Right ventricle dysfunction is a significant contributor to functional limitation and mortality in PAH.
Systemic and peripheral factors also play a role in exercise limitation and symptoms.
The relationship between exercise abnormalities and symptoms is complex and not fully elucidated.

Conclusions:

Further research is needed to fully understand the origins and significance of dyspnea and fatigue in PAH.
Clarifying the role of the RV and other factors can guide clinical management and improve patient outcomes.
Cardiopulmonary exercise testing may offer insights into RV dysfunction and exercise limitation in PAH.